21 results about "Rosacea flaccida" patented technology

Compositions and methods for treating and preventing inflammatory and autoimmune skin conditions, particularly rosacea, using one or more topically applied benzimidazole compounds in a pharmaceutically acceptable carrier for use on skin. A preferred benzimidazole compound comprises mebendazole. A treatment composition preferably comprises 0.05-0.075 weight percent mebendazole, and may comprise up to 20.0% mebendazole, in an aqueous carrier or vehicle comprising a cream, gel, lotion, liquid, emulsion, aerosol spray, non-aerosol spray,, suspension, or ointment and is applied at least once daily over a treatment period of at least two weeks to result in a reduction of cutaneous cytotoxic CD+8 T-cells, papules, pustules, swelling, appearance of redness or inflammation, and / or reduction in itchiness, and hot or burning sensation in the affected area compared to pre-treatment levels.

Compositions and methods for treating and preventing inflammatory and autoimmune skin conditions, particularly rosacea, using one or more topically applied benzimidazole compounds in a pharmaceutically acceptable carrier for use on skin. A preferred benzimidazole compound comprises mebendazole. A treatment composition preferably comprises 0.05-0.075 weight percent mebendazole, and may comprise up to 20.0% mebendazole, in an aqueous carrier or vehicle comprising a cream, gel, lotion, liquid, emulsion, aerosol spray, non-aerosol spray,, suspension, or ointment and is applied at least once daily over a treatment period of at least two weeks to result in a reduction of cutaneous cytotoxic CD+8 T-cells, papules, pustules, swelling, appearance of redness or inflammation, and / or reduction in itchiness, and hot or burning sensation in the affected area compared to pre-treatment levels.

The disclosure demonstrates the role of mast cell stabilizers in treating rosacea. The disclosure also shows the role of mast cells, cathelicidin, serine protease and / or vitamin D3 in rosacea pathology and the use of antagonists and inhibitors thereof to treat rosacea.

To provide a composition for use in the treatment or prevention of pathogenic infections, rosacea, eczema and psoriasis in humans or animals.SOLUTION: There is provided a composition comprising benzalkonium halide; didecyldimethylammonium halide; polyhexamethylene biguanide salt; bronopol; and p-chloro-m-cresol.SELECTED DRAWING: None

The present invention describes new cosmetic, cosmeceutical and / or pharmaceutical compositions, as well as their uses and useful methods for alleviating conditions arising from inflammatory processes, sensitive skin, rosacea, atopic dermatitis, eczema, and / or for alleviating the sensation of discomfort and pain, modulating the CB2 receptor, and / or for improving problems relating to cutaneous hyperchromia and disorders relating to increased sebogenesis.

【Solution】A composition and method for treating and preventing inflammatory and autoimmune skin conditions, particularly rosacea, using one or more topically applied benzimidazole compounds in a pharmaceutically acceptable carrier for use on the skin. Preferred benzimidazole compounds include mebendazole. The therapeutic composition preferably contains 0.05 to 0.20% by weight of mebendazole in an aqueous or non-aqueous carrier or vehicle including creams, gels, lotions, liquids, emulsions, microemulsions, aerosol sprays, non-aerosol sprays, serums, solutions, suspensions, or ointments, may contain up to 20.0% of mebendazole, and is applied at least once a day over a treatment period of at least two weeks, resulting in a reduction in the appearance of skin cytotoxic CD+8 T cells, papules, pustules, swelling, redness or inflammation, and / or itching at the affected site compared to pre-treatment levels.

A pharmaceutical composition for treating moderate or severe rosacea comprises a formulated, body weight-independent low dose of minocycline that reduces the severity of rosacea in at least 2 weeks with a decrease in lesion count, Investigator's Global Assessment (IGA) score, and Clinician's Erythema Assessment (CEA) score with a measured improvement in quality of life.

A cosmetic composition, advantageously ecobiological, comprising: - polyglutamic acid or one of its salts; and - at least one peptide derivative represented by the following general formula (I):, in which: - R1 represents a hydrogen atom, an acyl or acyloxy radical; and - R2 represents the side chain of an α-amino acid selected from the group consisting of: tryptophan, glutamic acid, arginine, cysteine, methionine, histidine and tyrosine; its use to combat skin redness and / or skin aging; its use to prevent and / or combat skin hypervascularization and / or skin inflammation and / or rosacea; as well as a process for selecting compounds suitable for preventing and / or combating these conditions.

The invention provides a composition comprising oleanolic acid and the salts, prodrug and solvates thereof; and one or more compounds selected from the following group: ellagic acid, adenine, betaine, choline, miquelianin, p-coumaric acid, pipecolic acid, protocatechuic acid and tyramine, and the salts, prodrugs and solvates thereof. Such a composition is for use in reducing lipid levels in sebocytes, and the composition may find use in treating acne vulgaris and rosacea.

Topical compositions including β-alanine and a transient receptor potential cation channel subfamily M (melastatin) member 8 (TRPM8) agonist, such as menthol, are disclosed. Also disclosed are methods of decreasing skin inflammation or redness in a subject, and methods of decreasing frequency or duration of symptoms of inflammatory skin conditions, such as rosacea.

Methods for enhanced dermal delivery of adapalene esters to treat skin conditions including acne, rosacea, and photoaging are described. The invention is based on the discovery that applying lipophilic adapalene esters to non-disinfected skin and / or with preserved natural microflora results in significantly enhanced penetration and therapeutic and non-therapeutic efficacy compared to conventional protocols involving preliminary skin disinfection. The methods avoid antimicrobial pretreatments, preserve beneficial skin microorganisms, and achieve high absorption and penetration of the adapalene ester while maintaining safety and reducing treatment complexity.

A method of topically applying to skin a composition comprising a water soluble Phoenix dactylifera seed extract, an essential oil from the leaves of tea tree, an aqueous Myrothamnus flabellifolia leaf and stem extract, and a saccharide isomerate comprising an exopolysaccharide of Vibrio alginolyticus is disclosed.

Methods and compositions for the treatment of skin disorders (e.g., acne, rosacea) are described.

The disclosure demonstrates the role of mast cell stabilizers in treating rosacea. The disclosure also shows the role of mast cells, cathelicidin, serine protease and / or vitamin D3 in rosacea pathology and the use of antagonists and inhibitors thereof to treat rosacea.

A method for treating active acne or any other inflammatory skin condition, such as, but not limited to, rosacea, psoriasis, and the like is disclosed comprising using a microneedling device capable of achieving certain specific depths which are controllable by the user and a medical grade anti-inflammatory antibacterial antioxidant oil which is applied to the treatment area both before and after the microneedling. In a preferred embodiment, the oil is a medical grade CBD tincture with organic hempseed oil. The treatment is repeated until satisfactory resolution of the acne or any other inflammatory skin condition that is being treated has been achieved.

The present invention generally relates to the field of skin care. More particularly. the invention relates to a cosmetic or therapeutic skin care composition comprising at least one of the skin-health promoting Staphylococcus strains selected from the group of Staphylococcusepidermidis HAC26 and Staphylococcus warneri HAA333 or a culture supernatant of any of these. The invention also provides a method for treating or preventing atopic dermatitis and / or rosacea by applying the skin care composition of the invention to a skin area in need of treatment. The invention also relates to the use of a skin care composition of the invention for treating or preventing atopic dermatitis and / or rosacca.

The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.

The present invention provides an antimicrobial peptide and its pharmaceutical composition that is highly stable, safe, has good antimicrobial activity, and has a shorter sequence, and can treat and alleviate rosacea, adolescent acne, atopic dermatitis, genital warts and vulvar intraepithelial neoplasia, inflammatory reactions, inflammatory response syndromes, etc., and the antimicrobial polypeptide contains the amino acid sequence Ac-SRMKKWAKIIEKWRKWH-NH2.

Disclosed are compositions and their use for the treatment of human skin, particularly facial skin, to alleviate the symptoms of cosmetic or dermatologic skin conditions. The compositions include black willow bark extract, cats claw extract, and dragon's blood extract. The compositions ameliorate skin conditions including acne, rosacea, blemish, dermatitis, eczema, or the like.

A regimen and a pharmaceutical composition for the treatment of a skin condition and / or skin affliction are described. The regimen includes topically applying to the skin of a subject in need of such treatment a pharmaceutical composition comprising about 2.5% w / w to about 10% w / w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient.

The present invention relates to processes for obtaining a plant extract of flowering tops of Inula helenium, and also to Inula helenium plant extracts, to compositions comprising same, and to the uses thereof for preventing and / or treating a chronic inflammatory skin disorder, in particular a pigmentary disorder, in particular (i) a pigmentary spot, in particular an actinic lentigo, (ii) a post-inflammatory hyperpigmentation, in particular associated with a scar or with an unaesthetic disorder consecutive to an inflammatory skin manifestation, in particular a scar or an acne mark, a scar or a rosacea mark or (iii) melasma.